Scientist II / Senior Scientist, I, tLNP Process Development

About the role

The target lipid nanoparticle (tLNP) process development team is seeking a highly motivated, talented, and innovative scientist to develop manufacturing processes for tLNP from purified mRNA into purified tLNP bulk drug product. The successful candidate will help advance understanding unit operations such as mRNA encapsulation, bioconjugation, and tangential flow filtration, as well as scaling up lab processes into pre-clinical, clinical, and commercial scale manufacturing processes. Targeted lipid nanoparticles (tLNPs) represent a key new modality to enable the effective delivery of mRNA. The tLNP chemistry, manufacturing, and control (CMC) team (TCT) is a newly formed group under Biologics CMC, Development Sciences, R&D. The tLNP CMC team focuses on process development for tLNPs, including mRNA process development, tLNP process development, and formulation development. The tLNP process development team within TCT is responsible for developing the manufacturing process for tLNP from bulk drug substance (purified mRNA) into bulk drug product (purified tLNPs). The process starts from mixing purified mRNA and lipid components to form mRNA encapsulated LNPs, then conjugating the LNPs with a targeting moiety, and lastly purifying the tLNPs with tangential flow filtration. The tLNP process development team will work together with mRNA process development team, tLNP formulation team, and analytical development team. The team will also collaborate closely with various functions and Center of Excellences within Biologics CMC and Synthetic Molecule CMC departments. The end goal for tLNP process development team is to deliver a robust manufacturing process at commercial scale. This includes science-based, hands-on approaches in the lab to optimizing process parameters and understanding impact of process parameters on critical quality attributes. First-principle based and statistical modeling can be applied where appropriate. Along the pharmaceutical development life cycle, the team will be responsible for successful production of non-GMP pre-clinical safety study supply and GMP clinical study supply from a manufacturing plant on site or at third party manufacturers. The team will also lead the tech transfer of commercial process into a commercial facility. Additionally, the team reviews appropriate sections of Common Technical Document (CTD) for regulatory submissions. Building strong cross-functional relationships with internal and external partners is key to the team's success. The work will contribute to cutting-edge mRNA-based therapeutics.